During the past decade, Capital Area Research LLC conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 13 clinical trials were completed, i.e. on average, 40.6% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 12 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Capital Area Research LLC" #1 sponsor was "Eli Lilly and Company" with 9 trials, followed by "Bayer" with 4 trials sponsored, "Amgen" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Capital Area Research LLC" #1 collaborator was "Duke Clinical Research Institute" with 2 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Capital Area Research LLC" are "Obesity" (5 trials), "Overweight" (3 trials), "Type 2 Diabetes" (3 trials), "Atrial Fibrillation" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Capital Area Research LLC" in a lesser frequency.

Most popular intervention types in "Capital Area Research LLC" are "Drug" (23 trials), "Other" (6 trials), "Biological" (4 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Tirzepatide" (6 trials), "Dulaglutide" (2 trials), "LY3502970" (2 trials) and "ARO-ANG3" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital Area Research LLC" are 34 trials for "All" genders.

Currently, there are NaN active trials in "Capital Area Research LLC". undefined are not yet recruiting, 7 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Capital Area Research LLC, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Capital Area Research LLC, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".